Japan & International — European Patent Office

Japan: Japan is identified as a strategic market for Dyadic International due to its leadership in various biotechnology sectors, and this patent allowance facilitates Dyadic International's expansion and business development efforts within the country.

International — European Patent Office: The International — European Patent Office allowed claims covering Dyadic International's proprietary Thermothelomyces heterothallica recombinant protein expression technology, providing significant intellectual property protection for the company in Japan.

Japan: Japan is the jurisdiction where the patents were granted, an important oncology market.

International — European Patent Office: The International — European Patent Office granted and allowed the patents, acting as the regulatory authority.

Japan: Patent granted or allowed in Japan.

International — European Patent Office: EPO granted a second European patent for aggression treatment.